UK Peptide and Weight-Loss Medication Statistics 2026
This page collects market, regulatory and consumer-safety statistics for the UK peptide and weight-loss medication sector, each linked to its primary source (NICE, NHS England, the MHRA and official records). Every figure was re-checked against that primary source in July 2026. Where a source could not be re-reached, the figure is shown with the period it was published for and is marked as not re-verified, rather than restated as current. It is editorial comparison and information, not medical advice, and makes no health claims about any compound. Last updated July 2026. Every figure below links to its primary source.
3.4m people in England are estimated to be eligible for tirzepatide under NICE guidance (a BMI of 35 or more plus a weight-related condition). Source: NHS England, interim commissioning guidance (NICE TA1026)
Weight-loss medication in the UK
people in England are estimated to be eligible for tirzepatide under NICE guidance (a BMI of 35 or more plus a weight-related condition). (2025 eligible cohort, re-verified July 2026) Source: NHS England, interim commissioning guidance (NICE TA1026)
people are expected to start NHS tirzepatide in the first three years of the phased primary-care rollout. (2025 to 2028, re-verified July 2026) Source: NHS England, interim commissioning guidance (NICE TA1026)
is the UK legal status of every GLP-1 weight-loss medicine: prescription-only, supplied only after an assessment by a qualified prescriber. (in force, re-verified July 2026) Source: MHRA, gov.uk (29 December 2025)
Consumer safety and enforcement
of illegally traded medicines, close to 20 million doses, were seized by the MHRA. (2025, re-verified July 2026) Source: MHRA, gov.uk press release (26 January 2026)
of the 42 integrated care boards in England had started prescribing tirzepatide in line with the rollout two months after launch. (2025 figure as published, not re-verified in July 2026) Source: House of Commons Library, weight-loss medicines briefing
PeptideClear data
UK peptide and weight-loss retailers are tracked in the PeptideClear register. The 25 research-peptide sellers among them are scored in the CoA Trust Index on certificate-of-analysis transparency and company verification, and a further 15 clinics, pharmacies and brands are profiled without a CoA score. First-party data (July 2026) Source: PeptideClear CoA Trust Index See the CoA Trust Index
Our own data
The figures marked "First-party data" above are published by PeptideClear from its own dataset and are not available elsewhere. The full methodology and the underlying table are in the CoA Trust Index.
Methodology and sources
Every statistic on this page is taken from a named primary source and links to the original record so you can verify it. We do not republish figures from secondary blogs. The page is reviewed and the figures refreshed on a regular cadence; the "last updated" date reflects the most recent substantive change, not an automated rebuild.
Cite this page
To reference these figures, please credit PeptideClear and link to this page:
Source: PeptideClear, UK Peptide and Weight-Loss Medication Statistics 2026, https://peptideclear.co.uk/statistics/ (accessed July 2026).
Compiled by Oliver Mackman. Published by PeptideClear.